The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes
Open accessAbstract
Background: Both Alzheimer’s disease (AD) and type 2 diabetes (T2D) share common pathological features including inflammation, insulin signaling alterations, or vascular damage. AD has no successful treatment, and the close relationship between both diseases supports the study of antidiabetic drugs to limit or slow down brain pathology in AD. Empagliflozin (EMP) is a sodium-glucose co-transporter 2 inhibitor, the newest class of antidiabetic agents. EMP controls hyperglycemia and reduces cardiovascular comorbidities and deaths associated to T2D. Therefore, we have analyzed the role of EMP at the central level in a complex mouse model of AD-T2D. Methods: We have treated AD-T2D mice (APP/PS1xdb/db mice) with EMP 10 mg/kg for 22 weeks. Glucose, insulin, and body weight were monthly assessed. We analyzed learning and memory in the Morris water maze and the new object discrimination test. Postmortem brain assessment was conducted to measure brain atrophy, senile plaques, and amyloid-β levels. Tau phosphorylation, hemorrhage burden, and microglia were also measured in the brain after EMP treatment. Results: EMP treatment helped to maintain insulin levels in diabetic mice. At the central level, EMP limited cortical thinning and reduced neuronal loss in treated mice. Hemorrhage and microglia burdens were also reduced in EMP-treated mice. Senile plaque burden was lower, and these effects were accompanied by an amelioration of cognitive deficits in APP/PS1xdb/db mice. Conclusions: Altogether, our data support a feasible role for EMP to reduce brain complications associated to AD and T2D, including classical pathological features and vascular disease, and supporting further assessment of EMP at the central level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575
Diabetes, a New Mutation in the Mouse
Hummel, K. P., Dickie, M. M., & Coleman, D. L. (1966) · Science · doi:10.1126/science.153.3740.1127 · Cited by 990
Lin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., & Kim-Mitsuyama, S. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0148-1 · Cited by 423
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Nauck, M. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s50773 · Cited by 343
Cai, X., Yang, W., Gao, X., Chen, Y., Zhou, L., Zhang, S., Han, X., & Ji, L. (2018) · Obesity · doi:10.1002/oby.22066 · Cited by 181
Neeland, I. J., McGuire, D. K., Chilton, R., Crowe, S., Lund, S. S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115616901 · Cited by 168
Hayden, M., Grant, D., Aroor, A., & DeMarco, V. (2019) · Brain Sciences · doi:10.3390/brainsci9030057 · Cited by 93
van der Kooij, M. A., Jene, T., Treccani, G., Miederer, I., Hasch, A., Voelxen, N., Walenta, S., & Müller, M. B. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1804412115 · Cited by 92
Shaikh, S., Rizvi, S. M. D., Shakil, S., Riyaz, S., Biswas, D., & Jahan, R. (2016) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1319 · Cited by 70
Cited by
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
Tian, S., Jiang, J., Wang, J., Zhang, Z., Miao, Y., Ji, X., & Bi, Y. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3673 · Cited by 79
Shin, A., Koo, B. K., Lee, J. Y., & Kang, E. H. (2024) · BMJ · doi:10.1136/bmj-2024-079475 · Cited by 69
The overall impact of COVID ‐19 on healthcare during the pandemic: A multidisciplinary point of view
Sabetkish, N., & Rahmani, A. (2021) · Health Science Reports · doi:10.1002/hsr2.386 · Cited by 68
Metadata
- Authors
- Hierro-Bujalance, C., Infante-Garcia, C., del Marco, A., Herrera, M., Carranza-Naval, M. J., Suarez, J., Alves-Martinez, P., Lubian-Lopez, S., & Garcia-Alloza, M.
- Venue
- Alzheimer's Research & Therapy
- Published
- 2020-04-07
- Volume
- 12
- Issue
- 1
- Pages
- 40-40
- ISSN
- 1758-9193 (ISSN-L)
- OpenAlex
- W3014778405
- Cited by
- 181
- References
- 11
- FWCI
- 10.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes. https://app.cochat.ai/papers/10.1186/s13195-020-00607-4
- The paper
- Hierro-Bujalance, C., Infante-Garcia, C., del Marco, A., Herrera, M., Carranza-Naval, M. J., Suarez, J., Alves-Martinez, P., Lubian-Lopez, S., & Garcia-Alloza, M. (2020). Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer’s disease and type 2 diabetes. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-020-00607-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.